Variation in therapeutic strategies for the management of severe COVID‐19 in India: A nationwide cross‐sectional survey
Bharat Jagiasi, Prashant Nasa, Gunjan Chanchalani, Ahsan Ahmed, Ajith Kumar Ak, Kanwalpreet Sodhi, Kishore Mangal, Manoj K Singh, Nitesh Gupta, Prasanna U Bidkar, Ranvir S Tyagi, Reshu G Khanikar, Swagata Tripathy, Swapna Khanzode, Kesavarapu Subba Reddy, Saurabh Saigal, Vijay Anand Sivakumar, Yash Javeri, Seema S Tekwani
International Journal of Clinical Practice, doi:10.1111/ijcp.14574
Aim: During the pandemic of coronavirus disease 2019 (COVID-19), the physicians are using various off-label therapeutics to manage COVID-19. We undertook a crosssectional survey to study the current variation in therapeutic strategies for managing severe COVID-19 in India. Methods: From January 4 to January 18, 2021, an online cross-sectional survey was conducted among physicians involved in the management of severe COVID-19. The survey had three sections: 1. Antiviral agents, 2. Immunomodulators, and 3. Adjuvant therapies. Results: 1055 respondents (from 24 states and five union territories), of which 64.2% were consultants, 54.3% working in private hospitals, and 39.1% were from critical care medicine completed the survey. Remdesivir (95.2%), antithrombotics (94.2%),
prescribed antibiotics with severity of COVID-19 (58.3%) or increased inflammatory markers (56.4%) were preferred indications. There was significant variation in the use of adjuvant therapies with specialists from critical care medicine preferred use of antibiotics in severe and critical COVID-19, while anaesthesiologists preferred vitamins in all patients of COVID-19. Bacterial co-infections are uncommon in COVID-19 and vary from 3.5% at the time of admission to 15% among hospitalised patients. 28 A recent guideline on antimicrobials in COVID-19, recommended a restrictive approach and empirical antibiotics to be considered only if clinical, imaging and biochemical markers suggest a bacterial co-infection. The de-escalation of antibiotics within 48 hours is suggested if representative cultures or antigen tests excluded bacterial co-infection. 29 The authors did not recommend any empirical antibiotic regimen and advised to use community or hospital-acquired pneumonia guidelines while starting antibiotics and using local antimicrobial surveillance. 29 Recently, the RECOVERY trial found no role of azithromycin in the treatment of hospitalised COVID-19 patients. 30 The prepublication release from the PRINCIPAL trial using azithromycin or doxycycline for 14 days showed no significant benefit in time to recovery or hospitalisation. 31 NIH does not recommend vitamin C in COVID-19 because of insufficient data. 32 There are ongoing trials on intravenous vitamin C in..
References
Agarwal, Mukherjee, Kumar, Convalescent plasma in the management of moderate covid-19 in adults in India:open label phase II multicentre randomised controlled trial (PLACID Trial), BMJ
Alhazzani, Evans, Alshamsi, Surviving sepsis campaign guidelines on the management of adults with coronavirus disease 2019 (COVID-19) in the ICU: first update, Crit Care Med
Armstrong, Kane, Cook, Outcomes from intensive care in patients with COVID-19: a systematic review and meta-analysis of observational studies, Anaesthesia
Asch, Sheils, Islam, Variation in US hospital mortality rates for patients admitted with COVID-19 during the first 6 months of the pandemic, JAMA Intern Med
Beigel, Tomashek, Dodd, Remdesivir for the treatment of covid-19 -final report, N Engl J Med
Berlin, Gulick, Martinez, Severe covid-19, N Engl J Med
Borczuk, Salvatore, Seshan, COVID-19 pulmonary pathology: a multi-institutional autopsy cohort from Italy and New York City, Mod Pathol
Charan, Kaur, Bhardwaj, Snapshot of COVID-19 related clinical trials in India, Indian J Clin Biochem
Chatterjee, Is India missing COVID-19 deaths?, Lancet
Chow, Khanna, Kethireddy, Aspirin use is associated with decreased mechanical ventilation, ICU admission, and inhospital mortality in hospitalized patients with COVID-19, Anesth Analg
Dong, Du, Gardner, An interactive web-based dashboard to track COVID-19 in real time, Lancet Infect Dis
Gopalan, Misra, COVID-19 pandemic and challenges for socio-economic issues, healthcare and National Health Programs in India, Diabetes Metab Syndr
Grasselli, Greco, Zanella, Risk factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy, Italy, JAMA Intern Med
He, Yi, Zhu, Estimation of the basic reproduction number, average incubation time, asymptomatic infection rate, and case fatality rate for COVID-19: meta-analysis and sensitivity analysis, J Med Virol
Horby, Lim, Emberson, Dexamethasone in hospitalized patients with covid-19 -preliminary report, N Engl J Med
Janiaud, Axfors, Schmitt, Association of convalescent plasma treatment with clinical outcomes in patients with COVID-19: a systematic review and meta-analysis, JAMA
Joshi, Parkar, Ansari, Role of favipiravir in the treatment of COVID-19, Int J Infect Dis
Lim, Subramaniam, Reddy, Case fatality rates for patients with COVID-19 requiring invasive mechanical ventilation. a meta-analysis, Am J Respir Crit Care Med
Murdaca, Pioggia, Negrini, Vitamin D and Covid-19: an update on evidence and potential therapeutic implications, Clin Mol Allergy
News, PRINCIPLE trial finds antibiotics azithromycin and doxycycline not generally effective treatments for COVID-19
Nice, COVID-19 rapid evidence summary: Tocilizumab for COVID-19
Nih, The COVID-19 Treatment Guidelines Panel's Statement on the Use of Ivermectin for the Treatment of COVID-19
Onder, Rezza, Brusaferro, Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy, JAMA
Pan, Peto, Henao-Restrepo, Repurposed antiviral drugs for covid-19 -Interim WHO Solidarity trial results, N Engl J Med
Parr, Time to Reassess Tocilizumab's Role in COVID-19 Pneumonia, JAMA Intern Med
Sieswerda, De Boer, Bonten, Recommendations for antibacterial therapy in adults with COVID-19 -an evidence based guideline, Clin Microbiol Infect
Sterne, Murthy, Association between administration of systemic corticosteroids and mortality among critically Ill patients with COVID-19: a meta-analysis, JAMA
Wise, Covid-19: Arthritis drugs improve survival in intensive care patients, shows study, BMJ
Wu, Mcgoogan, Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention, JAMA
Zhou, Yu, Du, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet
